---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-136647"
form_type: "8-K"
ticker: "HSCS"
cik: "0001468492"
company_name: "HeartSciences Inc."
filed_at: "2024-12-16T23:59:59+00:00"
generated_at: "2026-05-29T02:52:52.272154+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# HeartSciences reports Q2 FY2025 zero revenue; cash $4.1M; MyoVista device on track for FDA submission Q1 2025

## Summary
- No revenue in Q2 FY2025; cash and equivalents $4.1M, shareholders' equity ~$4.0M at Oct 31, 2024.
- MyoVista wav ECG device on track for FDA submission around Q1 2025; final pre-submission meeting with FDA requested.
- MyoVista Insights Phase 1 (no regulatory clearance) completion by end of 2024; test sites targeted H1 2025. Phase 2 AI-ECG clearance target H2 2025.
- Pre-validation of Mount Sinai-licensed low ejection fraction AI-ECG algorithm progressing; CMS 2025 OPPS final rule includes reimbursement path.

## SEC filing metadata
- accession: 0000950170-24-136647
- form_type: 8-K
- ticker: HSCS
- cik: 0001468492
- company_name: HeartSciences Inc.
- filed_at: 2024-12-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468492/000095017024136647/0000950170-24-136647-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468492/000095017024136647/hscs-20241216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-136647
- JSON: https://secwatch.observer/filing/0000950170-24-136647.json
- Plain text: https://secwatch.observer/filing/0000950170-24-136647.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.